Activist Denner gets his way with a board seat at troubled Ariad

Sarissa Capital Management founder Alex Denner

Alex Denner doesn't join a company's board without raising some eyebrows. He has a history of shaking things up, and now he's taken a seat with the board of directors at Ariad ($ARIA)--a position he demanded back in October when the company's only approved drug, Iclusig, ran into major safety concerns. Formerly healthcare head of notorious proxy rebel Carl Icahn's firm, Denner struck out on his own in 2011 to found Sarissa Capital, which is Ariad's second-largest shareholder. Story | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…